A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Sponsor:

SWOG

Sponsor Study ID:

S1900K

CTO #:

104055

NCT Number:

NCT06031688

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lung

Study Objectives:

The primary objective is to compare the response rate (confirmed or unconfirmed, complete or partial) between participants with MET exon 14 skipping positive NSCLC randomized to tepotinib with or without ramucirumab. To compare the frequency of all-grade treatment- related peripheral edema as defined by CTCAE between the arms. To evaluate the frequency and severity of toxicities within each arm. To compare progression-free survival between the arms. To compare overall survival between the arms. To estimate the duration of response (DoR) among responders within each arm

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)